SciBX
Science-Business eXchange

THE DISTILLERY

This week in therapeutics

Indication	Target/marker/ pathway	Summary	Licensing status	Publication and contact information
Neurology				
Guillain-Barré syndrome (GBS); chronic inflammatory demyelinating polyradiculoneuropathy (CIDP)	Myelin protein zero (MPZ; P0)	Studies in mice suggest that targeting P0 could be useful for treating GBS or CIDP. $CD4^+$ T cells generated from the $CD4^+$ T cells of neuropathic mice were highly specific for P0, suggesting that P0 is a dominant self-antigen recognized by T cells and autoantibodies. T cells from a transgenic mouse specific for a P0 epitope were sufficient to induce a fulminant form of autoimmune peripheral neuropathy resembling GBS and CIDP. Next steps include validating the P0-specific response in humans and exploring its therapeutic potential in animal models of GBS and CIDP. *SciBX* 2(9); doi:10.1038/scibx.2009.371 Published online March 5, 2009	Patent status not applicable; unlicensed	Louvet, C. *et al. J. Exp. Med.*; published online Feb. 16, 2009; doi:10.1084/jem.20082113 **Contact:** Jeffrey A. Bluestone, University of California, San Francisco, Calif. e-mail: jbluest@diabetes.ucsf.edu